Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER

BACKGROUND: Despite strong evidence of benefit, uptake of newer glucose-lowering medications that reduce cardiovascular risk has been low. We sought to examine global trends and predictors of use of SGLT2i and GLP-1 RA in patients with type 2 diabetes. METHODS: DISCOVER is a global, prospective, obs...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnold, Suzanne V., Tang, Fengming, Cooper, Andrew, Chen, Hungta, Gomes, Marilia B., Rathmann, Wolfgang, Shimomura, Iichiro, Vora, Jiten, Watada, Hirotaka, Khunti, Kamlesh, Kosiborod, Mikhail
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040320/
https://www.ncbi.nlm.nih.gov/pubmed/35473607
http://dx.doi.org/10.1186/s12902-022-01026-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040320/
https://www.ncbi.nlm.nih.gov/pubmed/35473607
http://dx.doi.org/10.1186/s12902-022-01026-2

Ejemplares similares